Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Clinical trial NCT03818672 · TERMINATED

Trial details

NCT number: NCT03818672
Sponsor: Bausch Health Americas, Inc.
Status: TERMINATED
Phase: Phase 4
Study type: INTERVENTIONAL

Severe Hepatic Impairment

Start date: 2019-01-29
Primary completion: 2020-02-02
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.